Does anyone know why it states in the Bell Potter report that "at an annual reimbursement of $100,000 per patient, Rett Syndrome wouldrepresent a US$1.6bn market and Fragile X would represent a US$7bn market in the US alone", while earlier in their report they state that peak worldwide annual sales will be 500m and 700m for Rett and Fragile X?
Is it something to do with licensing?
Ann: Investor Presentation, 8 January 2015, page-46
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |